Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Dow
Johnson and Johnson
Medtronic
Baxter

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,022,279

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,022,279 protect, and when does it expire?

Patent 8,022,279 protects VYXEOS and is included in one NDA.

This patent has thirteen patent family members in eleven countries.

Summary for Patent: 8,022,279
Title:Liposomal formulations of anthracycline agents and cytidine analogs
Abstract: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.
Inventor(s): Mayer; Lawrence (North Vancouver, CA), Johnstone; Sharon (Vancouver, CA), Harasym; Troy (North Vancouver, CA)
Assignee: Celator Pharmaceuticals, Inc. (Princeton, NJ)
Application Number:11/587,112
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,022,279

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes   Start Trial   Start Trial Y FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,022,279

PCT Information
PCT FiledApril 22, 2005PCT Application Number:PCT/CA2005/000625
PCT Publication Date:November 03, 2005PCT Publication Number: WO2005/102359

International Family Members for US Patent 8,022,279

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005235455   Start Trial
Canada 2564542   Start Trial
Cyprus 1113012   Start Trial
European Patent Office 1744764   Start Trial 122018000134 Germany   Start Trial
European Patent Office 1744764   Start Trial 300960 Netherlands   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
AstraZeneca
Colorcon
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.